Gemeinschaftspraxis Drs. med. Wilke/Wagner/Petzoldt/Angerer
- Address
- Jakob-Henle-Straße 1, 90766 Fürth, Germany
Gemeinschaftspraxis Drs. med. Wilke/Wagner/Petzoldt/Angerer - Breast Cancer Research Center
This medical group practice specializes in clinical oncology research with a primary focus on early breast cancer treatment strategies. The center has demonstrated extensive expertise in evaluating novel therapeutic approaches for various breast cancer subtypes, particularly in the adjuvant and neoadjuvant settings. Their research portfolio encompasses innovative combination therapies aimed at improving disease-free survival outcomes for patients with early-stage disease.
- Hormone receptor-positive (HR+/HER2-negative) breast cancer with targeted CDK4/6 inhibitor therapy
- Triple-negative breast cancer (TNBC) with immunotherapy combinations
- BRCA-mutated breast cancer with PARP inhibitor treatment strategies
The practice's clinical trial portfolio demonstrates a commitment to precision medicine approaches, including biomarker-driven therapies such as PARP inhibitors for patients with germline BRCA mutations and immune checkpoint inhibitors for triple-negative disease. Their participation in large-scale international Phase III trials reflects their capability to conduct complex oncology studies that combine neoadjuvant and adjuvant treatment strategies, contributing valuable data to advance breast cancer care standards globally.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gemeinschaftspraxis Drs. med. Wilke/Wagner/Petzoldt/Angerer
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Olaparib as Adjuvant Therapy in Germline BRCA1/2 Mutated High-Risk HER2-Negative Primary Breast Cancer: A Phase III Randomized Study | AstraZeneca AB | Phase III | Not Recruiting | Aug 2014 | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | 2018-06-13 | 2018-06-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.